Allogene Therapeutics Inc (ALLO) Stock: A Closer Look

Allogene Therapeutics Inc [ALLO] stock is trading at $4.38, up 0.23%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ALLO shares have gain 8.15% over the last week, with a monthly amount glided 38.17%, and seem to be holding up well over a long-time horizon.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

On 16, January 2024, Allogene Therapeutics Announces Participation in Upcoming Investor Conferences. In a post published today on Yahoo Finance, Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences in January and February.

From an analyst’s perspective:

Allogene Therapeutics Inc [NASDAQ: ALLO] stock has seen the most recent analyst activity on January 05, 2024, when JMP Securities downgraded its rating to a Mkt Perform.

Allogene Therapeutics Inc [ALLO] stock has fluctuated between $2.23 and $7.35 over the past year. Allogene Therapeutics Inc [NASDAQ: ALLO] shares were valued at $4.38 at the most recent close of the market.

Analyzing the ALLO fundamentals

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.27 points at the first support level, and at 4.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.49, and for the 2nd resistance point, it is at 4.60.

Allogene Therapeutics Inc [ALLO] reported earnings per share of -$0.37 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.52/share, meaning a difference of $0.15 and a surprise factor of 28.80%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.53 per share as compared to estimates of -$0.59 per share, a difference of $0.06 representing a surprise of 10.20%.

Ratios To Look Out For

For context, Allogene Therapeutics Inc’s Current Ratio is 12.58.

Transactions by insiders

Recent insider trading involved MESSEMER DEBORAH M., Director, that happened on Dec 18 when 18640.0 shares were sold. Director, Mayo Stephen completed a deal on Aug 07 to sell 10000.0 shares. Meanwhile, General Counsel Bhavnagri Veer sold 3000.0 shares on Feb 13.

Related Posts